, Cancer of the Pancreas-Cancer Stat Facts, 2017.

-. Infocancer, Appareil digestif-Cancer du pancréasMaladie-Epidémiologie, 2017.

A. Bouvier, M. David, V. Jooste, M. Chauvenet, C. Lepage et al., Rising incidence of pancreatic cancer in France, Pancreas, vol.39, issue.8, pp.1243-1249, 2010.

T. Kamisawa, L. D. Wood, T. Itoi, and K. Takaori, Pancreatic cancer. The Lancet, vol.388, pp.73-85, 2016.

S. Carrera, A. Sancho, E. Azkona, J. Azkuna, and G. Lopez-vivanco, Hereditary pancreatic cancer: related syndromes and clinical perspective. Hered Cancer Clin Pract, vol.15, p.9, 2017.

J. P. Neoptolemos, D. D. Stocken, H. Friess, C. Bassi, J. A. Dunn et al., A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer, N Engl J Med, vol.350, issue.12, pp.1200-1210, 2004.

J. P. Neoptolemos, D. D. Stocken, C. Bassi, P. Ghaneh, D. Cunningham et al.,

, Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection: A Randomized Controlled Trial, JAMA, vol.304, issue.10, pp.1073-81, 2010.

J. P. Neoptolemos, D. H. Palmer, P. Ghaneh, E. E. Psarelli, J. W. Valle et al., Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. The Lancet, vol.389, pp.1011-1035, 2017.

H. A. Burris, M. J. Moore, J. Andersen, M. R. Green, M. L. Rothenberg et al., Improvements in survival and clinical benefit with gemcitabine as first-line therapy for 61 patients with advanced pancreas cancer: a randomized trial, J Clin Oncol, vol.15, issue.6, pp.2403-2416, 1997.

M. J. Moore, D. Goldstein, J. Hamm, A. Figer, J. R. Hecht et al., Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol Off J Am Soc Clin Oncol, vol.25, issue.15, pp.1960-1966, 2007.

V. Hoff, D. D. Ervin, T. Arena, F. P. Chiorean, E. G. Infante et al., Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, N Engl J Med, vol.369, issue.18, pp.1691-703, 2013.

M. Pirmohamed, S. James, S. Meakin, C. Green, A. K. Scott et al., Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients, BMJ, vol.3, issue.7456, pp.15-24, 2004.

L. Marthey, A. Sa-cunha, J. F. Blanc, M. Gauthier, A. Cueff et al., FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort, Ann Surg Oncol, vol.22, issue.1, pp.295-301, 2015.

D. Meulendijks, A. Cats, J. H. Beijnen, and J. Schellens, Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity-Ready for clinical practice?, Cancer Treat Rev, vol.50, pp.23-34, 2016.

L. S. Schwartzberg, F. Rivera, M. Karthaus, G. Fasola, J. Canon et al., PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.32, issue.21, pp.2240-2247, 2014.

Y. Bang, E. Van-cutsem, A. Feyereislova, H. C. Chung, L. Shen et al., Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial, Lancet Lond Engl, vol.376, issue.9742, pp.687-97, 2010.

V. Chung, S. Mcdonough, P. A. Philip, D. Cardin, A. Wang-gillam et al., Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial, JAMA Oncol, vol.3, issue.4, pp.516-538, 2017.

B. Kaufman, R. Shapira-frommer, R. K. Schmutzler, M. W. Audeh, M. Friedlander et al., Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation, J Clin Oncol Off J Am Soc Clin Oncol, vol.33, issue.3, pp.244-50, 2015.

O. Boucher and P. Laurent-puig, Médecine personnalisée en cancérologie digestive Vers un traitement à la carte, 2013.

. Netgen, Cancer colorectal et sujets âgés : y a-t-il une spécificité de prise en charge ?, 2016.

A. Hurria, K. Togawa, S. G. Mohile, C. Owusu, H. D. Klepin et al., Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study, J Clin Oncol, vol.29, issue.25, p.3457, 2011.

C. Prado, V. E. Baracos, L. J. Mccargar, T. Reiman, M. Mourtzakis et al., Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment, Clin Cancer Res Off J Am Assoc Cancer Res, vol.15, issue.8, pp.2920-2926, 2009.

D. Srdic, S. Plestina, A. Sverko-peternac, N. Nikolac, A. Simundic et al., Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value. Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.24, pp.4495-502, 2016.

I. Ray-coquard, C. Borg, T. Bachelot, C. Sebban, I. Philip et al., Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy, Br J Cancer, vol.88, issue.2, pp.181-187, 2003.

N. Cézé, G. Thibault, G. Goujon, J. Viguier, H. Watier et al., Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy, Cancer Chemother Pharmacol, vol.68, issue.5, pp.1305-1318, 2011.

R. A. Fleming, G. Milano, A. Thyss, M. C. Etienne, N. Renée et al., Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients, Cancer Res, vol.52, issue.10, pp.2899-902, 1992.

A. Van-kuilenburg, Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5fluorouracil, Eur J Cancer, vol.40, issue.7, pp.939-50, 2004.

J. Ciccolini, DPD deficiency in patients treated with fluorouracil, Lancet Oncol, vol.16, issue.16, pp.1574-1580, 2015.

M. Launay, L. Dahan, M. Duval, A. Rodallec, G. Milano et al., Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer, Br J Clin Pharmacol, vol.81, issue.1, pp.124-154, 2016.

C. Serdjebi, G. Milano, and J. Ciccolini, Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs, Expert Opin Drug Metab Toxicol, vol.11, issue.5, pp.665-72, 2015.

C. Serdjebi, J. Seitz, J. Ciccolini, M. Duluc, E. Norguet et al., Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen, Pharmacogenomics, vol.14, issue.9, pp.1047-51, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01708020

M. Whirl-carrillo, E. Mcdonagh, J. Hebert, L. Gong, K. Sangkuhl et al., Pharmacogenomics Knowledge for Personalized Medicine, Clin Pharmacol Ther, 2012.

T. Aparicio, M. Ducreux, and S. Chaussade, 5-fluorouracile : données sur le métabolisme et place actuelle dans le traitement des cancers digestifs

, Fluoropyrimidine Pathway, Pharmacodynamics [Internet]. PharmGKB, 2017.

, Fluoropyrimidine Pathway, Pharmacokinetics, 2009.

Z. Imam, G. Thérizols, A. Vincent, F. Lafôrets, M. P. Espinoza et al., Translational reprogramming of colorectal cancer cells induced by 5-fluorouracil through a miRNAdependent mechanism, Oncotarget, vol.8, issue.28, pp.46219-46252, 2017.

L. Dean, . Therapy, V. Pratt, H. Mcleod, L. Dean et al., Medical Genetics Summaries

. Bethesda, National Center for Biotechnology Information (US

, Antimetabolite Pathway-Folate Cycle, Pharmacodynamics [Internet]. PharmGKB, p.2017

I. Pathway and . Pharmacokinetics, , 2009.

, Les alkylants doubles brins, 2017.

P. Perego and J. Robert, Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy, Cancer Chemother Pharmacol, vol.77, issue.1, pp.5-18, 2016.

L. V. Kalman, J. Agúndez, M. L. Appell, J. L. Black, G. C. Bell et al., Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting

, Clin Pharmacol Ther, vol.99, issue.2, pp.172-85, 2016.

E. Boyer, J. Thomas, F. Quaranta, S. Picard, N. Loriot et al., UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice, Fundam Clin Pharmacol. 2015 juin, vol.29, issue.3, pp.219-256

T. M. Sissung, B. C. English, D. Venzon, W. D. Figg, and J. F. Deeken, Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform, Pharmacogenomics, 2010.

C. D'engremont, D. Vernerey, A. Pointet, G. Simone, F. Fein et al., Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study, BMC Cancer, vol.16, issue.1, p.823, 2016.

B. Tan, L. A. Birdsell, L. Martin, V. E. Baracos, and K. Fearon, Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer, Clin Cancer Res Off J Am Assoc Cancer Res, vol.15, issue.22, pp.6973-6982, 2009.

, Annotation of CPIC Guideline for fluorouracil and DPYD [Internet]. PharmGKB, p.2017

, Annotation of PRO Guideline for irinotecan and UGT1A1, p.2017

X. Ding, W. Chen, H. Fan, and B. Zhu, Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy, Gene, vol.559, issue.1, pp.31-38, 2015.

A. Khatri, B. W. Williams, J. Fisher, R. C. Brundage, V. J. Gurvich et al., SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours, Br J Cancer, vol.110, issue.2, pp.304-316, 2014.

C. Mclean, A. Wilson, and R. B. Kim, Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?, J Clin Pharmacol, vol.56, pp.40-58, 2016.

L. Huang, T. Zhang, C. Xie, X. Liao, Q. Yu et al., SLCO1B1 and SLC19A1 Gene Variants and Irinotecan-Induced Rapid Response and Survival: A Prospective Multicenter Pharmacogenetics Study of Metastatic Colorectal Cancer, PLOS ONE, vol.8, issue.10, p.77223, 2013.

D. J. Crona, J. Ramirez, W. Qiao, A. De-graan, M. J. Ratain et al., Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study

, Pharmacogenomics J, vol.16, issue.1, pp.54-63, 2016.

L. Tarasova, I. Kalnina, K. Geldnere, A. Bumbure, R. Ritenberga et al., Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients, Pharmacogenet Genomics, vol.22, issue.9, pp.659-66, 2012.

D. Paolo, A. Polillo, M. Capecchi, M. Cervetti, G. Baratè et al., The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia, Pharmacogenomics J, vol.14, issue.4, pp.328-363, 2014.
URL : https://hal.archives-ouvertes.fr/in2p3-00373791

, Genes and Immunity-Sequence variation, linkage disequilibrium and association with Crohn's disease on chromosome 5q31, 2017.

Q. Chen, F. Meng, L. Wang, Y. Mao, H. Zhou et al., A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients. Sci Rep, vol.7, p.7059, 2017.

D. Vrana, J. Novotny, I. Holcatova, I. Hlavata, and P. Soucek, CYP1B1 gene polymorphism modifies pancreatic cancer risk but not survival, Neoplasma, vol.57, issue.1, pp.15-24, 2010.

G. The, Estrogen Metabolism, and Cancer Risk

G. Food, , 2016.

M. Klüppel, P. Samavarchi-tehrani, K. Liu, J. L. Wrana, and A. Hinek, C4ST-1/CHST11-controlled chondroitin sulfation interferes with oncogenic HRAS signaling in Costello syndrome, Eur J Hum Genet, vol.20, issue.8, pp.870-877, 2012.

M. Ferro, G. Giuberti, S. Zappavigna, S. Perdonà, G. Facchini et al., Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms, Oncol Rep, vol.27, issue.2, pp.409-424, 2012.